drugset / Trial / NCT01761019

A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy

NCT01761019

Phase 4 Completed 8 enrolled University of Pittsburgh LEO Pharma · collab
NaSingle-groupOpen-labelTreatment

Summary

Oral therapies for psoriasis, including methotrexate and acitretin, are often less effective when used as monotherapy (without other oral medicines or creams) than are newer biologic injected drugs. However, these oral medications are also less expensive than biologic agents and may be safer for use in some patients. The purpose of this study is to determine if adding a topical psoriasis medicine, calcipotriene/betamethasone topical suspension (Taclonex topical suspension), will improve the severity of psoriasis in patients already on methotrexate or acitretin and to determine if adding this topical suspension will reduce the desire of such patients to switch to a biologic agent to treat their psoriasis.

Timeline

Start
2013-01
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule 0.005 % Topical
Subject betamethasone dipropionate Small molecule 0.064 % Topical

Indications